Cantor Fitzgerald maintains Overweight rating on Nyxoah, $3 price target

Nyxoah reported Q3 results, with an EPS loss of €0.18 and revenue of €9.2M, up 365% year-over-year. The company also announced a new CEO and interim CFO.

Nyxoah SA (NYXH) reported Q3 2026 revenue of EUR9.2M, up 365% YoY. CEO Liam Kelly highlighted U.S. market opportunities, adjusted FY 2026 revenue guidance to EUR33M-EUR35M, and progress in CCC PMA supplement submission. The company trained 80 new surgeons and activated 53 new accounts. CMS reimbursement for Genio procedure increased by 11-13%. Cash position was EUR77.1M as of Q3 2026.

Nyxoah SA (NYXH) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Third Quarter 2026 Financial and Operating Results Global net revenue was €9.2 million driven by 29% sequential U.S. net revenue growth PMA supplement submitted to the FDA to expand Genio’s U.S. indication to include Complete Conc

Nyxoah SA (NYXH) presented 12-month data from its ACCCESS study on the Genio system for sleep apnea, meeting efficacy endpoints. AHI responder rate was 77.2%, ODI 87.7%. No device-related serious adverse events occurred. The company submitted a PMA supplement to the FDA to expand the Genio system's indication.

Nyxoah SA reported 12-month ACCCESS data showing a 74.3% median AHI reduction with Genio in CCC OSA patients. The company filed a PMA supplement with the FDA to expand Genio’s indication to CCC patients, with no serious adverse events reported. According to Nyxoah, a positive FDA decision could be a significant commercial catalyst.

Nyxoah SA (NYXH) shares rose 11.9% after its ACCCESS U.S. study met primary safety and efficacy endpoints. The Genio system showed a 77.2% Apnea-Hypopnea Index responder rate and zero device-related serious adverse events. The company plans to submit a premarket approval supplement to the FDA for expanded indication.